These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 11531265

  • 1. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
    Monks NR, Blakey DC, Curtin NJ, East SJ, Heuze A, Newell DR.
    Br J Cancer; 2001 Sep 01; 85(5):764-71. PubMed ID: 11531265
    [Abstract] [Full Text] [Related]

  • 2. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
    Monks NR, Calvete JA, Curtin NJ, Blakey DC, East SJ, Newell DR.
    Br J Cancer; 2000 Jul 01; 83(2):267-9. PubMed ID: 10901381
    [Abstract] [Full Text] [Related]

  • 3. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D.
    Br J Cancer; 2001 Jun 15; 84(12):1671-6. PubMed ID: 11401322
    [Abstract] [Full Text] [Related]

  • 4. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
    Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF, Springer CJ.
    Cancer Res; 1996 Jul 15; 56(14):3287-92. PubMed ID: 8764123
    [Abstract] [Full Text] [Related]

  • 5. DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.
    Monks NR, Blakey DC, East SJ, Dowell RI, Calvete JA, Curtin NJ, Arris CE, Newell DR.
    Eur J Cancer; 2002 Jul 15; 38(11):1543-52. PubMed ID: 12110502
    [Abstract] [Full Text] [Related]

  • 6. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC, Melton RG, Niculescu-Duvaz I.
    J Med Chem; 1995 Dec 22; 38(26):5051-65. PubMed ID: 8544182
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH.
    Cancer Res; 1999 Aug 15; 59(16):3998-4003. PubMed ID: 10463598
    [Abstract] [Full Text] [Related]

  • 8. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Spooner R, Davies L, Marais R, Springer CJ.
    J Med Chem; 1998 Dec 17; 41(26):5297-309. PubMed ID: 9857097
    [Abstract] [Full Text] [Related]

  • 9. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
    Khan TH, Eno-Amooquaye EA, Searle F, Browne PJ, Osborn HM, Burke PJ.
    J Med Chem; 1999 Mar 25; 42(6):951-6. PubMed ID: 10090777
    [Abstract] [Full Text] [Related]

  • 10. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ, Niculescu-Duvaz I.
    Anticancer Drug Des; 1995 Jul 25; 10(5):361-72. PubMed ID: 7639927
    [Abstract] [Full Text] [Related]

  • 11. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
    Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R, Springer CJ.
    Cancer Res; 2007 May 15; 67(10):4949-55. PubMed ID: 17510425
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, Sharma SK, Springer CJ, Mauger AB, Melton RG.
    Br J Cancer; 1995 Nov 15; 72(5):1083-8. PubMed ID: 7577451
    [Abstract] [Full Text] [Related]

  • 13. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH.
    Clin Cancer Res; 2000 Mar 15; 6(3):765-72. PubMed ID: 10741695
    [Abstract] [Full Text] [Related]

  • 14. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I, Scanlon I, Niculescu-Duvaz D, Friedlos F, Martin J, Marais R, Springer CJ.
    J Med Chem; 2004 May 06; 47(10):2651-8. PubMed ID: 15115406
    [Abstract] [Full Text] [Related]

  • 15. Ultrasound Enhances ZD2767P-Carboxypeptidase G2 against Chemoresistant Ovarian Cancer Cells by Altering the Intracellular Pharmacokinetics of ZD2767D.
    Liu Q, Zhong X, Zhang Y, Li X, Qian G, Yu T.
    Mol Pharm; 2020 Jun 01; 17(6):1922-1932. PubMed ID: 32302486
    [Abstract] [Full Text] [Related]

  • 16. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ, Antoniw P, Bagshawe KD, Wilman DE.
    Anticancer Drug Des; 1991 Nov 01; 6(5):467-79. PubMed ID: 1764165
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
    Masterson LA, Spanswick VJ, Hartley JA, Begent RH, Howard PW, Thurston DE.
    Bioorg Med Chem Lett; 2006 Jan 15; 16(2):252-6. PubMed ID: 16290933
    [Abstract] [Full Text] [Related]

  • 18. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
    Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Lehouritis P, Marais R, Springer CJ.
    J Med Chem; 2003 Apr 24; 46(9):1690-705. PubMed ID: 12699387
    [Abstract] [Full Text] [Related]

  • 19. Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl.
    Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ.
    Leuk Res; 2005 May 24; 29(5):565-72. PubMed ID: 15755509
    [Abstract] [Full Text] [Related]

  • 20. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
    Spooner RA, Martin J, Friedlos F, Marais R, Springer CJ.
    Cancer Gene Ther; 2000 Oct 24; 7(10):1348-56. PubMed ID: 11059693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.